These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 24265052)
1. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses. Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052 [TBL] [Abstract][Full Text] [Related]
2. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts]. Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532 [TBL] [Abstract][Full Text] [Related]
4. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Muenzer J Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732 [TBL] [Abstract][Full Text] [Related]
5. Current and new therapies for mucopolysaccharidoses. Penon-Portmann M; Blair DR; Harmatz P Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587 [TBL] [Abstract][Full Text] [Related]
6. Unique medical issues in adult patients with mucopolysaccharidoses. Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591 [TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919 [TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies. Nan H; Park C; Maeng S Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633 [No Abstract] [Full Text] [Related]
9. Glycosaminoglycans in mucopolysaccharidoses and other disorders. Khan SA; Nidhi F; Leal AF; Celik B; Herreño-Pachón AM; Saikia S; Benincore-Flórez E; Ago Y; Tomatsu S Adv Clin Chem; 2024; 122():1-52. PubMed ID: 39111960 [TBL] [Abstract][Full Text] [Related]
10. [Principles of therapeutic approaches for mucopolysaccharidoses]. Caillaud C Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383 [TBL] [Abstract][Full Text] [Related]
11. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses. Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095 [TBL] [Abstract][Full Text] [Related]
13. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231 [TBL] [Abstract][Full Text] [Related]
14. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Kakkis E; Marsden D Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments. Sawamoto K; Stapleton M; Alméciga-Díaz CJ; Espejo-Mojica AJ; Losada JC; Suarez DA; Tomatsu S Drugs; 2019 Jul; 79(10):1103-1134. PubMed ID: 31209777 [TBL] [Abstract][Full Text] [Related]
16. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses. Peck SH; Casal ML; Malhotra NR; Ficicioglu C; Smith LJ Mol Genet Metab; 2016 Aug; 118(4):232-43. PubMed ID: 27296532 [TBL] [Abstract][Full Text] [Related]
18. Substrate reduction therapies for mucopolysaccharidoses. Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626 [TBL] [Abstract][Full Text] [Related]
19. Radiologic and neuroradiologic findings in the mucopolysaccharidoses. Lachman R; Martin KW; Castro S; Basto MA; Adams A; Teles EL J Pediatr Rehabil Med; 2010; 3(2):109-18. PubMed ID: 21791838 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation effects on spinal cord compression in Hurler. Ferrara G; Maximova N; Zennaro F; Gregori M; Tamaro P Pediatr Transplant; 2014 May; 18(3):E96-9. PubMed ID: 24483599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]